Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations
- Start of industrial development of Sarconeos (BIO101) with a view to market access in severe forms of Covid-19 (COVA)
- Approvals to start the Phase 3 trial in the United States and Belgium in sarcopenia (SARA), a world first, opening up the prospect of partnerships
- Cash position and secured financing giving visibility of over 12 months
Biophytis publishes its half-year accounts as of 30 June 2023 and provides an update on the progress of its R&D projects over the 1st half of the year and the last few months.
Stanislas Veillet, Chairman and CEO of Biophytis, stated: “During the first half of 2023, we achieved key milestones in the development of our main drug candidate, Sarconeos (BIO101), with a view to partnerships and market access in 2024, despite a particularly challenging financial environment.
Pursuant to an accelerated development over the last two years, we have obtained positive results from our phase 2-3 COVA. Biophytis is one of the few European companies to have obtained proof of efficacy in patients with severe forms of COVID-19. We are pursuing the pharmaceutical and regulatory development of Sarconeos (BIO101), and are currently in discussions with European and American regulatory agencies to define the conditions for market access.
In addition, thanks to the encouraging results obtained with the SARA-INT phase 2b study, Biophytis has received authorizations from the US and Belgian agencies to start the clinical SARA-31 study, which will be the first phase 3 study ever launched in sarcopenia.
Finally, the Company has strengthened its management team over the last few months, notably in pharmaceutical operations, finance and business development, in order to forge strategic partnerships for the development of Sarconeos (BIO101).With the progress made in its pipeline, Biophytis is confirming its pioneering position in the development of treatments for age-related diseases, generating a strong medical need that is set to grow very rapidly in the years ahead.”